|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.42 AUD | -6.67% |
|
+18.31% | +21.74% |
| Apr. 24 | Immutep Shows Positive Data in Trial to Treat Squamous Cell Cancers in Head, Neck | MT |
| Apr. 24 | Immutep Limited Announces Positive Preliminary Topline Results from TACTI-003 Cohort B | CI |
Immutep Limited reported earnings results for the half year ended December 31, 2023. For the half year, the company reported revenue was AUD 4.11 million compared to AUD 2.58 million a year ago. Net loss was AUD 21.23 million compared to AUD 20.62 million a year ago.
Basic loss per share from continuing operations was AUD 0.0179 compared to AUD 0.0236 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| +21.74% | 326M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
IMMUTEP LIMITED 
